Genomics is advancing precision medicine and improving patient health and wellness. We are at a place now with NGS-based comprehensive genomic profiling where one biopsy, one test, and one report can lead to improved outcomes for cancer patients.
Doctors are using genomics to help identify the cause of undiagnosed rare diseases, helping families avoid years of hospital visits and unnecessary tests. Additionally, genomics is driving the field of pharmacogenomics, potentially leading to better outcomes for both individuals and healthcare providers through improved medication safety and efficacy and lowered medical costs.
Genomics has many benefits in precision medicine. Next-generation sequencing (NGS) can sequence multiple genes at once, identify disease-associated variants to help match patients to therapies or assess disease risk, and help target therapies and reduce overall care costs.
Genomics-powered precision health with NGS also offers the highest likelihood of rare disease diagnosis 9,10. Genomics in precision medicine is becoming a mainstay in clinical labs so it’s no longer just a research tool, and the cost has dropped dramatically. It’s time to consider how NGS precision medicine can support your institution in providing better patient care.
An overview of how we arrived at precision medicine for cardiovascular disease and where we are today with precision genomics-based therapeutics.
Improvements in DNA sequencing accuracy and throughput and genome interpretation software have made whole-genome sequencing an increasingly viable approach for precision diagnosis in clinical care.
Clinical and public health microbiology laboratories are increasingly adopting metagenomics into their existing laboratory workflows for infectious disease detection.
This iconic U.S.-based health care system will advance research and personalized medicine from Mexico City to Montreal and beyond.
We’re committed to advancing and individualizing the way cancer will be identified and treated. We want to partner with you in helping propel progress in personalized oncology.
The field of pharmacogenomics can lead to better outcomes for both individuals and healthcare providers through improved medication safety and efficacy and lowered medical costs.
Sudden cardiac arrest is a leading cause of non-traumatic fatality in the US. Genetics can help identify people at risk for familial hypercholesterolemia and early cardiovascular disease.